Insiders who reported open-market trades in the last 12 months at the companies Eric Bjerkholt files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Christopher Peetz - $16.29M in MIRM purchases and sales in the last 12 months
Patrick J. Heron - $9.00M in MIRM purchases and sales in the last 12 months
Michael G. Grey - $7.20M in MIRM purchases and sales in the last 12 months
Jolanda Howe - $5.55M in MIRM purchases and sales in the last 12 months
Peter Radovich - $2.32M in MIRM purchases and sales in the last 12 months
Joanne Quan - $1.46M in MIRM purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Eric Bjerkholt is a corporate insider, tracked as CHIEF FINANCIAL OFFICER of Mirum Pharmaceuticals, Inc. (MIRM). InsiderAlpha holds 19 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Eric Bjerkholt submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Eric Bjerkholt been buying or selling stock?
Recorded transactions: 0 open-market purchases and 16 open-market sales ($4.38M) across all tracked filings.
Eric Bjerkholt is CHIEF FINANCIAL OFFICER of Mirum Pharmaceuticals, Inc. (MIRM). 19 SEC Form 4 filings on record going back to 2024, most recently on 15 September 2026. Most recent open-market trade: sold $978K of MIRM on 15 September 2026. Lifetime open-market sales: $4.38M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Eric Bjerkholt.
InsiderAlpha's records for Eric Bjerkholt go back to 2024: 19 primary Form 4 filings, an average of 6.3 per year. 10 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
